 |
Top 75 medical and healthcare startups in France
Sep 30, 2025 | By Jason Kwon | 16 |
1
Funding: $43.3M
NOVACYT develops cellular diagnostics with a growing portfolio of cancer and infectious disease products and services.
NOVACYT develops cellular diagnostics with a growing portfolio of cancer and infectious disease products and services.
2
Funding: $315.9M
Inventiva is a clinical stage biopharmaceutical company with an expertise in fibrosis, oncology and orphan diseases. We are focussing on diseases with a high unmet medical need where either no treatments are available, such as NASH and Systemic Sclerosis, or the current standard of care leaves important manifestations of the diseases unaffected, as it is the case in many lysosomal storage diseases.
Inventiva is a clinical stage biopharmaceutical company with an expertise in fibrosis, oncology and orphan diseases. We are focussing on diseases with a high unmet medical need where either no treatments are available, such as NASH and Systemic Sclerosis, or the current standard of care leaves important manifestations of the diseases unaffected, as it is the case in many lysosomal storage diseases.
3
Funding: €193.1M
ImCheck Therapeutics is a privately-held French biotech company pioneering the next generation of immune checkpoint modulators.
ImCheck Therapeutics is a privately-held French biotech company pioneering the next generation of immune checkpoint modulators.
4
Funding: $274.4M
We are a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, we leverage our integrated development platform by combining a gene therapy-based approach with our core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics.
We are a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, we leverage our integrated development platform by combining a gene therapy-based approach with our core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics.
5
Funding: €101.6M
MaaT Pharma (Microbiota as a Therapy) is intended to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment contributes to dysbiosis.
MaaT Pharma (Microbiota as a Therapy) is intended to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment contributes to dysbiosis.
8
Funding: $114.7M
Nabla is the developer of Nabla Copilot, an ambient AI that helps clinicians enjoy care again.
Nabla is the developer of Nabla Copilot, an ambient AI that helps clinicians enjoy care again.
9
Funding: €91M
SafeHeal develops Colovac, an innovative solution for the protection of digestive anastomosis, designed to reduce anastomotic complications.
SafeHeal develops Colovac, an innovative solution for the protection of digestive anastomosis, designed to reduce anastomotic complications.
10
Funding: $69.6M
Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.
Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.
11
Funding: €43M
SeqOne is a next generation genomic analysis for next generation healthcare.
SeqOne is a next generation genomic analysis for next generation healthcare.
12
Funding: $854.1M
Valneva is a pharmaceutical company focused on the prevention of infectious diseases with significant unmet medical need.
Valneva is a pharmaceutical company focused on the prevention of infectious diseases with significant unmet medical need.
13
Funding: $816.5M
Doctolib is an online and mobile booking platform that helps to find a specialist doctor nearby and make an appointment.
Doctolib is an online and mobile booking platform that helps to find a specialist doctor nearby and make an appointment.
14
Funding: €666M
Alan wants to make health insurance as simple as subscribing to a software-as-a-service product. It starts with clear pricing and transparent reimbursement policies.
Alan wants to make health insurance as simple as subscribing to a software-as-a-service product. It starts with clear pricing and transparent reimbursement policies.
15
Funding: $393.5M
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.
16
Funding: $304.1M
OWKIN is the AI startup that uses machine learning to augment medical and biology research. Our proprietary platform, OWKIN Socrates, uses machine learning technology to integrate biomedical images, genomics and clinical data to discover biomarkers and mechanisms associated with diseases and treatment outcomes.
OWKIN is the AI startup that uses machine learning to augment medical and biology research. Our proprietary platform, OWKIN Socrates, uses machine learning technology to integrate biomedical images, genomics and clinical data to discover biomarkers and mechanisms associated with diseases and treatment outcomes.
17
Funding: €258.1M
The mission of every team member at Carmat is to contribute to the development of innovative artificial organs – the artificial heart today, tomorrow other vital organs – to treat millions of patients affected by advanced disease of these organs and to restore their normal life.
The mission of every team member at Carmat is to contribute to the development of innovative artificial organs – the artificial heart today, tomorrow other vital organs – to treat millions of patients affected by advanced disease of these organs and to restore their normal life.
18
Funding: $247.7M
Genfit SA, a biopharmaceutical engages in the research and development of drugs for the prevention and treatment.
Genfit SA, a biopharmaceutical engages in the research and development of drugs for the prevention and treatment.
19
Funding: $210M
Tissium invents the next generation of synthetic polymers for tissue reconstruction
Tissium invents the next generation of synthetic polymers for tissue reconstruction
20
Funding: €175.8M
Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer (OncoMimics™ peptides). Enterome’s pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.
Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer (OncoMimics™ peptides). Enterome’s pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system.
